Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity
AssigneeLaboratorios Del Dr. Esteve, S.A.
InventorsHelmut Heinrich Buschmann, Xavier Codony-Soler
Life of this patent
Estimating the term…
Abstract
The present invention relates to an active substance combination comprising at least one compound with 5-HT6 receptor affinity, and at least NMDA-receptor ligand, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament.
Claims27
An active substance combination comprising:
- a first component comprising one or more compounds with 5-HT6 receptor affinity;
- and
- a second component comprising one or more NMDA-receptor ligands.
9-13. (canceled)
A pharmaceutical formulation, comprising an active substance combination, the active substance combination comprising one or more compounds with 5-HT6 receptor affinity and one or more NMDA-receptor ligands and one or more pharmacologically acceptable adjuvants.
23-25. (canceled)
A method for simultaneous NMDA-receptor inhibition and 5-HT6-receptor regulation, said method comprising administering to a patient in need of such a treatment a therapeutically effective amount of an active substance combination comprising one or more compounds with 5-HT6 receptor affinity and one or more NMDA-receptor ligands.
A method of treatment and/or prophylaxis of disorders related to food ingestion for prophylaxis and/or treatment of gastrointestinal tract disorders, for prophylaxis and/or treatment of Metabolic Syndrome, Peripheral Nervous System Disorders, Central Nervous System Disorders, arthritis, epilepsy, anxiety, panic, depression, cognitive disorders, memory disorders, cardiovascular diseases, senile dementia processes, schizophrenia, psychosis, infantile hyperkinesia (ADHD, attention deficit/hyperactivity disorder), pain, hypertensive syndrome, inflammatory diseases, immunologic diseases or for improvement of cognition, said method comprising administering to a patient in need of such a treatment a therapeutically effective amount of an active substance combination comprising one or more compounds with 5-HT6 receptor affinity and one or more NMDA-receptor ligands.
A method for prophylaxis and/or treatment of obesity, anorexia, cachexia, bulimia, diabetes, irritable bowel syndrome, Alzheimer's, Parkinson's or Huntington's Disease, said method comprising administering to a patient in need of such a treatment a therapeutically effective amount of an active substance combination comprising one or more compounds with 5-HT6 receptor affinity and one or more NMDA-receptor ligands.
Dependencies are inferred from the claim text.